10
Participants
Start Date
October 7, 2025
Primary Completion Date
October 31, 2040
Study Completion Date
October 31, 2040
MOv19-BBz CAR T cells
Autologous T cells engineered to express an extracellular single chain variable fragment (scFv) with FRa specificity.
Cyclophosphamide/Fludarabine
Cytotoxic chemotherapy agents used for lymphodepletion prior to MOv19-BBz CAR T cell administration.
FRa Expression Testing
Laboratory Developed Test used to determine subject eligibility
RECRUITING
University of Pennsylvania, Philadelphia
National Cancer Institute (NCI)
NIH
University of Pennsylvania
OTHER